ACRS Overview

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing novel small and large molecule product candidates for immuno-inflammatory diseases. Its proprietary KINect drug discovery platform coupled with its integrated discovery approach to small and large molecules enables the Company to identify and advance product candidates. It provides contract research services to third parties enabled by its early-stage research and development expertise. The contract research segment is engaged in the provision of laboratory services. Its product candidate pipeline includes Bosakitug (ATI-045), ATI-2138 and ATI-052. The Bosakitug (ATI-045) is an investigational, novel, humanized anti-Thymic stromal lymphopoietin (TSLP) monoclonal antibody that specifically binds to human TSLP, blocking its interaction with the receptor complex and disrupting signal transduction. Its other investigational product candidate is Lepzacitinib (ATI-1777).

Wall Street analysts forecast ACRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACRS is11.33 USD with a low forecast of 8.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Aclaris Therapeutics Inc revenue for the last quarter amounts to 2.00M USD, increased 37.18

Aclaris Therapeutics Inc. EPS for the last quarter amounts to -0.15 USD, increased 25.00

Aclaris Therapeutics Inc (ACRS) has 69 emplpoyees as of May 10 2026.

Today ACRS has the market capitalization of 688.54M USD.